Literature DB >> 19559109

Improved antibiotic-free DNA vaccine vectors utilizing a novel RNA based plasmid selection system.

Jeremy Luke1, Aaron E Carnes, Clague P Hodgson, James A Williams.   

Abstract

To ensure safety, regulatory agencies recommend elimination of antibiotic resistance markers from therapeutic and vaccine plasmid DNA vectors. Here, we describe the development and application of a novel antibiotic-free selection system. Vectors incorporate and express a 150 bp RNA-OUT antisense RNA. RNA-OUT represses expression of a chromosomally integrated constitutively expressed counter-selectable marker (sacB), allowing plasmid selection on sucrose. Sucrose selectable DNA vaccine vectors combine antibiotic-free selection with highly productive fermentation manufacturing (>1g/L plasmid DNA yields), while improving in vivo expression of encoded proteins and increasing immune responses to target antigens. These vectors are safer, more potent, alternatives for DNA therapy or vaccination.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19559109      PMCID: PMC2767433          DOI: 10.1016/j.vaccine.2009.06.017

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

1.  pCOR: a new design of plasmid vectors for nonviral gene therapy.

Authors:  F Soubrier; B Cameron; B Manse; S Somarriba; C Dubertret; G Jaslin; G Jung; C L Caer; D Dang; J M Mouvault; D Scherman; J F Mayaux; J Crouzet
Journal:  Gene Ther       Date:  1999-08       Impact factor: 5.250

2.  Escherichia coli strains that allow antibiotic-free plasmid selection and maintenance by repressor titration.

Authors:  R M Cranenburgh; J A Hanak; S G Williams; D J Sherratt
Journal:  Nucleic Acids Res       Date:  2001-03-01       Impact factor: 16.971

3.  Conditional-replication, integration, excision, and retrieval plasmid-host systems for gene structure-function studies of bacteria.

Authors:  A Haldimann; B L Wanner
Journal:  J Bacteriol       Date:  2001-11       Impact factor: 3.490

4.  Separate-component-stabilization system for protein and DNA production without the use of antibiotics.

Authors:  Cédric Y Szpirer; Michel C Milinkovitch
Journal:  Biotechniques       Date:  2005-05       Impact factor: 1.993

Review 5.  Plasmid DNA manufacturing technology.

Authors:  Aaron E Carnes; James A Williams
Journal:  Recent Pat Biotechnol       Date:  2007

6.  A novel antibiotic free plasmid selection system: advances in safe and efficient DNA therapy.

Authors:  Jürgen Mairhofer; Irene Pfaffenzeller; David Merz; Reingard Grabherr
Journal:  Biotechnol J       Date:  2008-01       Impact factor: 4.677

Review 7.  Counterselectable markers: untapped tools for bacterial genetics and pathogenesis.

Authors:  J M Reyrat; V Pelicic; B Gicquel; R Rappuoli
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

8.  A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates.

Authors:  Dan H Barouch; Zhi-yong Yang; Wing-pui Kong; Birgit Korioth-Schmitz; Shawn M Sumida; Diana M Truitt; Michael G Kishko; Janelle C Arthur; Ayako Miura; John R Mascola; Norman L Letvin; Gary J Nabel
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

9.  pDNAVACCultra vector family: high throughput intracellular targeting DNA vaccine plasmids.

Authors:  James A Williams; Jeremy Luke; Lance Johnson; Clague Hodgson
Journal:  Vaccine       Date:  2005-08-26       Impact factor: 3.641

10.  A splicing enhancer in the human fibronectin alternate ED1 exon interacts with SR proteins and stimulates U2 snRNP binding.

Authors:  A Lavigueur; H La Branche; A R Kornblihtt; B Chabot
Journal:  Genes Dev       Date:  1993-12       Impact factor: 11.361

View more
  34 in total

1.  Vector insert-targeted integrative antisense expression system for plasmid stabilization.

Authors:  Jeremy M Luke; Aaron E Carnes; Clague P Hodgson; James A Williams
Journal:  Mol Biotechnol       Date:  2011-01       Impact factor: 2.695

2.  Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine.

Authors:  Jeremy M Luke; Gregory G Simon; Jonas Söderholm; John S Errett; J Thomas August; Michael Gale; Clague P Hodgson; James A Williams
Journal:  J Virol       Date:  2010-11-24       Impact factor: 5.103

3.  Biomaterials at the interface of nano- and micro-scale vector-cellular interactions in genetic vaccine design.

Authors:  Charles H Jones; Anders P Hakansson; Blaine A Pfeifer
Journal:  J Mater Chem B       Date:  2014-09-12       Impact factor: 6.331

Review 4.  New generation of plasmid backbones devoid of antibiotic resistance marker for gene therapy trials.

Authors:  Gaëlle Vandermeulen; Corinne Marie; Daniel Scherman; Véronique Préat
Journal:  Mol Ther       Date:  2011-08-30       Impact factor: 11.454

5.  A mini-intronic plasmid (MIP): a novel robust transgene expression vector in vivo and in vitro.

Authors:  Jiamiao Lu; Feijie Zhang; Mark A Kay
Journal:  Mol Ther       Date:  2013-03-05       Impact factor: 11.454

6.  High-Level Production of Plasmid DNA by Escherichia coli DH5α ΩsacB by Introducing inc Mutations.

Authors:  Ram Narayan Trivedi; Parvez Akhtar; Jonathan Meade; Patrick Bartlow; Mohammad M Ataai; Saleem A Khan; Michael M Domach
Journal:  Appl Environ Microbiol       Date:  2014-09-12       Impact factor: 4.792

Review 7.  Antibiotic-free selection in biotherapeutics: now and forever.

Authors:  Charlotte Mignon; Régis Sodoyer; Bettina Werle
Journal:  Pathogens       Date:  2015-04-03

8.  Mini-intronic plasmid vaccination elicits tolerant LAG3+ CD8+ T cells and inferior antitumor responses.

Authors:  Viswa Teja Colluru; Christopher D Zahm; Douglas G McNeel
Journal:  Oncoimmunology       Date:  2016-09-02       Impact factor: 8.110

Review 9.  Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production.

Authors:  James A Williams; Aaron E Carnes; Clague P Hodgson
Journal:  Biotechnol Adv       Date:  2009-02-20       Impact factor: 14.227

Review 10.  The future of human DNA vaccines.

Authors:  Lei Li; Fadi Saade; Nikolai Petrovsky
Journal:  J Biotechnol       Date:  2012-09-07       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.